Forbes

Taking A Closer Look At Molnupiravir. Is Continued Use Justified?

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...
News Medical

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, ...
Healio

Molnupiravir cuts risk for severe COVID-19 symptoms — and possibly long COVID

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...
Monthly Prescribing Reference

FDA Authorizes Use of Oral Antiviral Molnupiravir for Mild to Moderate COVID-19

Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...
FiercePharma

Pfizer's oral antiviral might be better, but Merck still expects $5B-plus from molnupiravir in 2022

When a phase 3 study revealed 30% efficacy for Merck and Ridgeback’s COVID-19 oral antiviral—a significant drop from the 50% figure the company touted at the trial’s interim stage—concerns emerged ...
Fox Business

FDA authorizes second COVID-19 antiviral pill, Merck's molnupiravir

The Food and Drug Administration (FDA) on Thursday authorized the use of Merck and Ridgeback Biotherapeutics' molnupiravir pill for treating COVID-19, the second such emergency use authorization in ...
MedPage Today

Molnupiravir May Offer Modest 6-Month Benefits for High-Risk COVID Patients

People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months ...
FiercePharma

ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal

Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...
Tennessean

Tennessee increases availability of oral antivirals to treat COVID-19

Tennessee boosted its supply of oral antiviral coronavirus drugs in recent weeks, the Tennessee Department of Health said in a news release Tuesday. The state was only able to order a limited amount ...
News Medical

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United ...
Business Wire

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug ...
Business Wire

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies ...